文献速递淋巴瘤

RESONATE-2研究最长8年随访:伊布替尼一线治疗慢性淋巴细胞白血病患者

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

RESONATE-2三期研究纳入≥65岁、无del(17p)的初治慢性淋巴细胞白血病患者,随机接受伊布替尼420mg每日一次(n=136)或苯丁酸氮芥0.5-0.8mg/kg≤12周期(n=133)。中位随访82.7个月(范围0.1-96.6个月),伊布替尼较苯丁酸氮芥持续显著改善无进展生存(HR 0.154;95%CI 0.108-0.220),7年无进展生存率59% vs 9%,伊布替尼7年总生存率78%。

要点

  • 伊布替尼较苯丁酸氮芥持续显著改善无进展生存,HR 0.154(95%CI 0.108-0.220)。
  • 7年无进展生存率伊布替尼59% vs 苯丁酸氮芥9%,伊布替尼7年总生存率78%。
  • 高危基因组特征患者亦见无进展生存获益:del(11q) HR 0.033,未突变IGHV HR 0.112。

核心结论

  • 最长8年随访的RESONATE-2数据表明,伊布替尼一线治疗慢性淋巴细胞白血病持续获益,包括高危基因组特征患者。

研究设计与样本

  • RESONATE-2为三期研究,纳入≥65岁、既往未治疗、无del(17p)的慢性淋巴细胞白血病患者,1:1随机接受伊布替尼420mg每日一次至疾病进展/不可接受毒性(n=136)或苯丁酸氮芥0.5-0.8mg/kg≤12周期(n=133)。

主要发现

  • 中位随访82.7个月(范围0.1-96.6个月),伊布替尼较苯丁酸氮芥持续显著改善无进展生存(HR 0.154;95%CI 0.108-0.220)。
  • 7年无进展生存率伊布替尼59% vs 苯丁酸氮芥9%。
  • 高危基因组特征患者中,伊布替尼较苯丁酸氮芥随机组亦见无进展生存获益:del(11q) HR 0.033(95%CI 0.010-0.107),未突变免疫球蛋白重链可变区 HR 0.112(95%CI 0.065-0.192)。
  • 伊布替尼7年总生存率78%。
  • 不良事件发生率与既往5年随访一致;因不良事件暂停伊布替尼给药≥7天者79例、减量者31例,这些不良事件分别有85%(67/79)和90%(28/31)缓解或改善。

关键数值与推荐

  • 伊布替尼组7年无进展生存率59%,苯丁酸氮芥组9%。
  • 伊布替尼组7年总生存率78%。
  • 最长8年随访时42%患者仍在接受伊布替尼治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients (≥65 years) with previously untreated CLL, without del(17p), were randomly assigned 1:1 to once-daily ibrutinib 420 mg until disease progression/unacceptable toxicity (n = 136) or chlorambucil 0.5-0.8 mg/kg ≤12 cycles (n = 133). With up to 8 years of follow-up (range, 0.1-96.6 months; median, 82.7 months), significant PFS benefit was sustained for ibrutinib vs chlorambucil (hazard ratio [HR], 0.154; 95% confidence interval [CI], 0.108-0.220). At 7 years, PFS was 59% for ibrutinib vs 9% for chlorambucil. PFS benefit was also observed for ibrutinib- vs chlorambucil-randomized patients with high-risk genomic features: del(11q) (HR, 0.033; 95% CI, 0.010-0.107) or unmutated immunoglobulin heavy chain variable region (HR, 0.112; 95% CI, 0.065-0.192). OS at 7 years was 78% with ibrutinib. Prevalence of adverse events (AEs) was consistent with previous 5-year follow-up. Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively. With up to 8 years of follow-up, 42% of patients remain on ibrutinib. Long-term RESONATE-2 data demonstrate sustained benefit with first-line ibrutinib treatment for CLL, including for patients with high-risk genomic features. These trials were registered at www.clinicaltrials.gov as #NCT01722487 and #NCT01724346.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022. PMID: 35377947. doi:10.1182/bloodadvances.2021006434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。